Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Introgen Hints at Suit Against Benda/SiBiono

publication date: Jul 5, 2007
IP for Cancer Gene Therapy at Issue -- A Washington Post article published today looked at US cancer patients who are traveling to China to receive Gendicine, the gene therapy for cancer that is produced by Shenzhen SiBiono GeneTech in China, a company that is majority owned by Benda Pharma (BPMA) (see story). Although the interviewed patients are happy with their treatments - which they must pay for themselves - they are angry that the same medications are not available in the US. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital